Second Genome has engaged in a number of solutions-based collaborations for the profiling of our partners’ clinical trials. These collaborations have helped identify key microbial signatures for important clinical trials and through these and other similar studies, many science articles have been published in peer-reviewed journals. Although we no longer offer this as a service, our novel platform will identify microbiome signatures to accompany any broad collaboration we engage in with partners.

Our team is continuing to explore partnerships and collaborations related to our approach to microbiome science in our core disease focus areas.

Partnership with Bayer to Leverage the Second Genome Discovery Platform to Accelerate Protein Discovery for Agricultural Applications

The companies have developed a multi-year research agreement to accelerate the discovery of new microbiome-based solutions to help farmers better manage environmental challenges on their farms. The collaboration will leverage Bayer’s extensive genomic databases with Second Genome’s expertise in analyzing microbial function through big data metagenomics, protein discovery, machine learning, and predictive analytics. This research will immediately expand the sourcing and diversity of novel proteins for the development of next-generation insect-control solutions.

If you are interested in partnering with us, please reach out to us at partnering@secondgenome.com.

Scientific collaboration with Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC), Ireland

The focus of our collaboration with the APC at UCC is to identify bacterial species and mechanisms that are driving IBD biology. This alliance between academia and industry allows both groups to benefit from the other’s expertise and exchange ideas to accelerate new discoveries.

M3: Microbiome Metabolites and the Mind, a Collaboration with Stanford Medicine

Second Genome, Inc., and the Stanford University School of Medicine have received a Fast-Track 1R44 Small Business Innovation Research (SBIR) grant to study the relationship between the human microbiome and autism as a model to be generalized to other central nervous system diseases such as substance use disorders. This multi-year collaboration will enable the platform to evaluate a host of central nervous system disorders.

Our body is host to over a 100 trillion microbial cells that comprise the human microbiome. In fact, the number of microbial cells in our bodies likely outnumber human cells. We rely on our microbiome everyday for many different biological processes and these microbes are necessary for good health. While autism spectrum disorders (ASDs) have a strong genetic component, it is also believed that the gut microbiome may play a role in the condition. Several studies have examined the gut microbiomes of individuals with autism and support the idea of a strong link between the human microbiome and autism-related behaviors.

The M3 study aims to unravel the impact of the microbiome on the ASD phenotype. Leveraging the crowdsourced approach for our clinical study, we hope to overcome the limitations of previous studies and provide a better understanding of the mechanisms involved.